pyrroles has been researched along with Vitiligo in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 6 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kantor, J | 1 |
| Perche, P; Pichardo, R; Purvis, C | 1 |
| Frangos, J; Ganesan, AK; Guerra, R; Huang, V; Li, SJ; Mobasher, P | 1 |
| Craiglow, BG; Olamiju, B | 1 |
| Alikhan, M; Jogi, R; Nguyen, JK; Patel, AB; Schlichte, MJ | 1 |
| Ishida, Y; Kabashima, K; Otsuka, A; Yagi, K | 1 |
| Passeron, T | 1 |
| Harris, JE; King, BA; Liu, LY; Refat, MA; Strassner, JP | 1 |
| Ceric-Dehdari, P; Meurer, M | 1 |
| Heyes, C; Robertson, SJ; Ross, G; Varigos, GA; Vu, M | 1 |
| Heaton, H; Kim, SR; King, BA; Liu, LY | 1 |
| Dina, Y; McKesey, J; Pandya, AG | 1 |
| Abe, Y; Hayashi, M; Hozumi, Y; Okamura, K; Suzuki, T | 1 |
| McKesey, J; Pandya, AG | 1 |
| Craiglow, BG; King, BA | 1 |
| Ahmad Nasrollahi, S; Firooz, A; Hashemi, A; Nassiri Kashani, M; Samadi, A | 1 |
| Ceovic, R; Gulin, SJ; Kostovic, K; Mokos, ZB | 1 |
| Damsky, W; King, BA | 1 |
6 review(s) available for pyrroles and Vitiligo
| Article | Year |
|---|---|
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Topics: Adult; Arthritis, Rheumatoid; Female; Hidradenitis Suppurativa; Humans; Janus Kinase Inhibitors; Keratoacanthoma; Melanoma; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Psoriasis; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vitiligo | 2020 |
Medical and Maintenance Treatments for Vitiligo.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; alpha-MSH; Anti-Bacterial Agents; Calcineurin Inhibitors; Dinoprostone; Humans; Immunosuppressive Agents; Low-Level Light Therapy; Methotrexate; Minocycline; Oxytocics; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Ultraviolet Therapy; Vitamin D; Vitiligo | 2017 |
[Systemic treatment of vitiligo : Balance and current developments].
Topics: alpha-MSH; Animals; Biomarkers; Combined Modality Therapy; Disease Models, Animal; Humans; Immunosuppressive Agents; Interferon-alpha; Janus Kinases; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Ultraviolet Therapy; Vitiligo | 2017 |
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Topics: Alopecia Areata; Azetidines; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Janus Kinases; Nitriles; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Topics: Administration, Oral; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Vitiligo | 2017 |
JAK inhibitors in dermatology: The promise of a new drug class.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Azetidines; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
12 other study(ies) available for pyrroles and Vitiligo
| Article | Year |
|---|---|
This Month in JAAD International: December 2022: Topical management of vitiligo with Janus kinase inhibitors.
Topics: Administration, Topical; Alopecia Areata; Humans; Janus Kinase Inhibitors; Janus Kinases; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vitiligo | 2022 |
Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
Topics: Alopecia Areata; Female; Humans; Pyrroles; Vitiligo | 2022 |
Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo.
Topics: Humans; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Vitiligo | 2020 |
Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Topics: Child; Humans; Phototherapy; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2020 |
Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib.
Topics: Adult; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Vitiligo | 2021 |
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Topics: Adult; Aged; Autoimmunity; Chemokine CXCL10; Chemokine CXCL9; Combined Modality Therapy; Female; Humans; Janus Kinase 1; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Severity of Illness Index; Skin Pigmentation; Ultraviolet Therapy; Vitiligo | 2017 |
Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Topics: Adult; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Th2 Cells; Treatment Outcome; Vitiligo | 2017 |
Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Pigmentation; Ultraviolet Therapy; Vitiligo | 2018 |
Disorders of Hypopigmentation
Topics: Administration, Cutaneous; Administration, Oral; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Counseling; Dermatologic Agents; Diagnosis, Differential; Epidermis; Humans; Janus Kinases; Melanocytes; Mycosis Fungoides; Nitriles; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quality of Life; Skin Pigmentation; Tinea Versicolor; Vitiligo | 2019 |
Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Topics: Administration, Oral; Animals; Butanols; Disease Models, Animal; Humans; Janus Kinase Inhibitors; Mice; Mice, Hairless; Mice, Transgenic; Piperidines; Pyrimidines; Pyrroles; Skin Lightening Preparations; Skin Pigmentation; Treatment Failure; Vitiligo | 2019 |
A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Facial Dermatoses; Female; Humans; Male; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Skin Cream; Ultraviolet Therapy; Vitiligo | 2019 |
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Topics: Administration, Oral; Female; Humans; Janus Kinase 1; Janus Kinase 3; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Pigmentation; Treatment Outcome; Vitiligo | 2015 |